POPLAR is an ongoing phase II trial that randomized 287 patients to receive atezolizumab 1200 mg or docetaxel 75 mg/m2 with emphasis placed on PD-L1 expression of tumor cells and tumor-infiltrating immune cells [29]. The gene discussed is CD274; the disease is neoplasm.